Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

734 Articles

Jon C. Ogg | Nov 21, 2014 at 10:20 AM EST

5 Health Care Stocks That Need to Play Serious Catch Up

24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to…

Lee Jackson | Nov 15, 2014 at 9:15 AM EST

Insider Selling Surges as Markets Hit Record High

With the markets at or near record highs, the volume of insider selling has reached some of the highest levels…

Lee Jackson | Nov 13, 2014 at 9:15 AM EST

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand…

Jon C. Ogg | Nov 12, 2014 at 1:35 PM EST

Gilead Sees Large Insider Stock Sale Into Debt Offering

A Gilead Sciences bond offering and a key insider stock sale netting over $14 million should be considered by investors.

Chris Lange | Nov 12, 2014 at 8:40 AM EST

Biotech Short Interest Becomes Stock Specific (Updated)

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.

Lee Jackson | Oct 30, 2014 at 8:55 AM EDT

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to…

Chris Lange | Oct 29, 2014 at 7:55 AM EDT

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences reported disappointing third-quarter results after the market close on Monday.

Chris Lange | Oct 28, 2014 at 11:55 AM EDT

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.

Chris Lange | Oct 27, 2014 at 10:30 AM EDT

Biotech Short Interest Becomes Stock Specific

Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.

Lee Jackson | Oct 13, 2014 at 8:40 AM EDT

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech…

Lee Jackson | Oct 8, 2014 at 9:00 AM EDT

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

In a new research report, Deutsche Bank analysts suggest investors focus on sectors like technology, health care, financials and selected…

Lee Jackson | Oct 2, 2014 at 9:50 AM EDT

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

A new research report from Merrill Lynch highlights 10 top catalyst-driven ideas for the fourth quarter.

Jon C. Ogg | Sep 25, 2014 at 10:50 AM EDT

Short Sellers Make Moves in Key Biotech Stocks

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…

Lee Jackson | Sep 15, 2014 at 10:55 AM EDT

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

A new research report from UBS focuses on four top companies that are making great strides in treatments for patients…

Chris Lange | Sep 11, 2014 at 9:20 AM EDT

Short Sellers Remain Vigilant Against Biotechs

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest…

1 … 34 35 36 37 38 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

5 Health Care Stocks That Need to Play Serious Catch Up

Insider Selling Surges as Markets Hit Record High

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

Gilead Sees Large Insider Stock Sale Into Debt Offering

Biotech Short Interest Becomes Stock Specific (Updated)

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

What to Look For in Gilead Sciences Earnings Report

Biotech Short Interest Becomes Stock Specific

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Short Sellers Make Moves in Key Biotech Stocks

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Short Sellers Remain Vigilant Against Biotechs

Why the Pure Bitcoin-Miner Fund Crushed the Blockchain Basket, Up 184%

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

PepsiCo’s $200 Billion Stability Play Is Attracting Dividend Investors

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

"100 Million Percent Wrong" Suze Orman Rages At Social Security Expert's "Crazy" Advice

Why the Pure Bitcoin-Miner Fund Crushed the Blockchain Basket, Up 184%

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

Gilead Sciences : GILD

All Gilead Sciences Articles

5 Health Care Stocks That Need to Play Serious Catch Up

Insider Selling Surges as Markets Hit Record High

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

Gilead Sees Large Insider Stock Sale Into Debt Offering

Biotech Short Interest Becomes Stock Specific (Updated)

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

What to Look For in Gilead Sciences Earnings Report

Biotech Short Interest Becomes Stock Specific

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Short Sellers Make Moves in Key Biotech Stocks

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Short Sellers Remain Vigilant Against Biotechs

Why the Pure Bitcoin-Miner Fund Crushed the Blockchain Basket, Up 184%

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

PepsiCo’s $200 Billion Stability Play Is Attracting Dividend Investors

Featured Reads

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

"100 Million Percent Wrong" Suze Orman Rages At Social Security Expert's "Crazy" Advice